Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
43 pending office actions • 11 clients • 35 examiners • 20 art units • 0 of 43 (0%) have an AI response strategy ready
Johnson, Marcou, Isaacs & Nix, LLC focuses on Biotechnology & Pharmaceuticals. The firm has 2173 career applications. Its resolved allowance rate is 84.69 percent. The firm averages 4.81 office actions per allowance. There are 40 pending office actions.
The 84.69 percent allowance rate shows the firm's success rate across 2173 career applications. The average of 4.81 office actions per allowance reflects the prosecution effort required in the biotechnology sector. The 40 pending office actions represent the firm's current workload.
Based on the USPTO statutory response window for each pending office action. 12 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 12 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 only | 1 (2%) |
| §101 + other | 9 (21%) |
| §103 only | 7 (16%) |
| §112 only | 5 (12%) |
| Double-patenting only | 1 (2%) |
| Double-patenting + other | 9 (21%) |
| Multi-statute (no §101) | 10 (23%) |
| No statute on record | 1 (2%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| RAMIREZ, DELIA M | 4 | 65.1% | +56.3% |
| HUTSON, RICHARD G | 3 | 65.1% | +53.1% |
| LIPPOLIS, ALEXANDRA ROSE | 2 | 46.9% | +59.0% |
| PERSONS, JENNA L | 2 | 50.8% | +61.7% |
| LEITH, NANCY J | 2 | 74.7% | +44.1% |
| WEHBE, ANNE MARIE SABRINA | 1 | 57.2% | +43.4% |
| MARVICH, MARIA | 1 | 54.9% | +28.1% |
| KUCKLA, ANNA GRACE | 1 | 53.2% | +54.1% |
| FENSTERMACHER, JASON B | 1 | 46.9% | +38.0% |
| WANG, XIAOBEI | 1 | 65.4% | +48.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18248199 | HELITRON MEDIATED GENETIC MODIFICATION | LIPPOLIS, ALEXANDRA ROSE | 25d overdue |
| 18277904 | SURFACTANT COMPOSITIONS | OGDEN JR, NECHOLUS | 8d overdue |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | JOHNSON, ALLISON MARIE | 14d |
| 17786168 | GENOME EDITING USING REVERSE TRANSCRIPTASE ENABLED AND FULLY ACTIVE CRISPR COMPLEXES | LEE, JAE W | 33d |
| 19218176 | Electronic Proxy Voting Systems and Methods | FENSTERMACHER, JASON B | — |
| 18576909 | METHODS FOR DIFFERENTIATING AND SCREENING STEM CELLS | WESTON, ALYSSA G | — |
| 18574816 | BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISMS, COMPOSITIONS AND USES THEREOF | DICKENS, AMELIA NICOLE | — |
| 18271684 | REPROGRAMMABLE TNPB POLYPEPTIDES AND USE THEREOF | TATGE, LEXUS MARC | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18628213 | NANOPOROUS ALLOYS | WANG, XIAOBEI | 140d overdue |
| 18248199 | HELITRON MEDIATED GENETIC MODIFICATION | LIPPOLIS, ALEXANDRA ROSE | 25d overdue |
| 16450852 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 9d |
| 16450825 | NOVEL CRISPR ENZYMES AND SYSTEMS | RAMIREZ, DELIA M | 14d |
| 16954032 | CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | HUTSON, RICHARD G | 20d |
| 19329060 | VERY LONG CHAIN FATTY ACIDS FOR TREATMENT AND ALLEVIATION OF DISEASES | KUCKLA, ANNA GRACE | 23d |
| 19390128 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | WEHBE, ANNE MARIE SABRINA | — |
| 19355982 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | MARVICH, MARIA | — |
| Client (Assignee) | Pending OAs |
|---|---|
| MIT | 28 |
| Harvard University | 3 |
| U.S. Government | 3 |
| EPAX NORWAY AS | 2 |
| Proxymity Limited | 1 |
| Virginia Tech | 1 |
| Nestlé S.A. | 1 |
| Lankem | 1 |
| California Institute of Technology | 1 |
| Wti, Inc. | 1 |
| The Brigham and Women's Hospital Inc. | 1 |
| Art Unit | Apps |
|---|---|
| 1652 | 8 |
| 1637 | 6 |
| 1636 | 5 |
| 1634 | 3 |
| 1633 | 2 |
| 1681 | 2 |
| 1656 | 2 |
| 1626 | 1 |
| 3698 | 1 |
| 1784 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 19390128 | ENGINEERED ADENO-ASSOCIATED VIRUS CAPSIDS | Massachusetts Institute Of Technology | WEHBE, ANNE MARIE SABRINA | 1634 | §103 | Final Rejection | — | Pending | Nov 14, 2025 |
| 19355982 | ENGINEERED MUSCLE TARGETING COMPOSITIONS | Massachusetts Institute Of Technology | MARVICH, MARIA | 1634 | §112DP | Non-Final OA | — | Pending | Oct 10, 2025 |
| 19329060 | VERY LONG CHAIN FATTY ACIDS FOR TREATMENT AND ALLEVIATION OF DISEASES | Epax Norway AS | KUCKLA, ANNA GRACE | 1626 | §103 | Final Rejection | 23d | Pending | Sep 15, 2025 |
| 19218176 | Electronic Proxy Voting Systems and Methods | Proxymity Limited | FENSTERMACHER, JASON B | 3698 | §101§112 | Final Rejection | — | Pending | May 23, 2025 |
| 18628213 | NANOPOROUS ALLOYS | VIRGINIA POLYTECHNIC INSTITUTE AND STATE UNIVERSITY | WANG, XIAOBEI | 1784 | §103 | Non-Final OA | 140d overdue | Pending | Apr 05, 2024 |
| 18698929 | ENGINEERED CARDIAC MUSCLE COMPOSITIONS | Massachusetts Institute Of Technology | SINGH, ANOOP KUMAR | §102§103§112DP | Non-Final OA | — | Pending | Apr 05, 2024 | |
| 18576909 | METHODS FOR DIFFERENTIATING AND SCREENING STEM CELLS | Massachusetts Institute Of Technology | WESTON, ALYSSA G | 1633 | §101§102§112 | Non-Final OA | — | Pending | Jan 05, 2024 |
| 18574816 | BIFIDOBACTERIUM LONGUM TRANSITIONAL MICROORGANISMS, COMPOSITIONS AND USES THEREOF | Société des Produits Nestlé S.A. | DICKENS, AMELIA NICOLE | 1645 | §101§102§103§112DP | Non-Final OA | — | Pending | Dec 28, 2023 |
| 18277904 | SURFACTANT COMPOSITIONS | Lankem Ltd. | OGDEN JR, NECHOLUS | 1761 | §101§102§103§112 | Final Rejection | 8d overdue | Pending | Aug 18, 2023 |
| 18271684 | REPROGRAMMABLE TNPB POLYPEPTIDES AND USE THEREOF | Massachusetts Institute Of Technology | TATGE, LEXUS MARC | 1637 | §101§102§103§112DP | Non-Final OA | — | Pending | Jul 11, 2023 |
| 18349707 | NOVEL CAS13B ORTHOLOGUES CRISPR ENZYMES AND SYSTEMS | Massachusetts Institute Of Technology | HUTSON, RICHARD G | 1652 | §102§112DP | Non-Final OA | — | Pending | Jul 10, 2023 |
| 18270131 | CROSS-NEUTRALIZING SARS-COV2 ANTIBODIES | California Institute Of Technology | JADHAO, SAMADHAN JAISING | 1672 | §101§112 | Non-Final OA | — | Pending | Jun 28, 2023 |
| 18032868 | REPROGRAMMABLE ISCB NUCLEASES AND USES THEREOF | Massachusetts Institute Of Technology | SU-TOBON, QIWEN NMN | 1636 | §112DP | Final Rejection | 9d | Pending | Apr 20, 2023 |
| 18248199 | HELITRON MEDIATED GENETIC MODIFICATION | Massachusetts Institute Of Technology | LIPPOLIS, ALEXANDRA ROSE | 1637 | §102§103 | Non-Final OA | 25d overdue | Pending | Apr 06, 2023 |
| 17928355 | CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS AND METHODS OF USE THEREOF | Massachusetts Institute Of Technology | STAVROU, CONSTANTINA E | 1632 | §103Other | Final Rejection | — | Pending | Nov 29, 2022 |
| 17912889 | COMPOSITIONS AND METHODS FOR ENHANCED LENTIVIRAL PRODUCTION | Massachusetts Institute Of Technology | SPENCER, ANDREA LYNNE MORRIS | 1631 | §103DP | Final Rejection | — | Pending | Sep 20, 2022 |
| 17910497 | NOVEL CAS ENZYMES AND METHODS OF PROFILING SPECIFICITY AND ACTIVITY | Massachusetts Institute Of Technology | CHONG, KIMBERLY | 1636 | §112 | Non-Final OA | — | Pending | Sep 09, 2022 |
| 17801815 | NOVEL TYPE IV AND TYPE I CRISPR-CAS SYSTEMS AND METHODS OF USE THEREOF | Massachusetts Institute Of Technology | PENNINGTON, KATIE LEIGH | 1634 | §101§102§103§112 | Final Rejection | — | Pending | Aug 24, 2022 |
| 17798248 | FIELD DEPLOYABLE CRISPR-CAS DIAGNOSTICS AND METHODS OF USE THEREOF | Massachusetts Institute Of Technology | PRIEST, AARON A | 1681 | §102§103DP | Non-Final OA | — | Pending | Aug 08, 2022 |
| 17788781 | GUIDED EXCISION-TRANSPOSITION SYSTEMS | Massachusetts Institute Of Technology | WOOLWINE, SAMUEL C | 1681 | §102§103§112 | Non-Final OA | — | Pending | Jun 24, 2022 |
| 17786168 | GENOME EDITING USING REVERSE TRANSCRIPTASE ENABLED AND FULLY ACTIVE CRISPR COMPLEXES | Massachusetts Institute Of Technology | LEE, JAE W | 1656 | §102§103§112 | Final Rejection | 33d | Pending | Jun 16, 2022 |
| 17785070 | PROGRAMMABLE DNA NUCLEASE-ASSOCIATED LIGASE AND METHODS OF USE THEREOF | Massachusetts Institute Of Technology | PERSONS, JENNA L | 1637 | §103§112 | Final Rejection | — | Pending | Jun 14, 2022 |
| 17776269 | SMALL TYPE II CAS PROTEINS AND METHODS OF USE THEREOF | Massachusetts Institute Of Technology | LIPPOLIS, ALEXANDRA ROSE | 1637 | §101§102§103§112Other | Final Rejection | — | Pending | May 12, 2022 |
| 17742503 | CRISPR-ASSOCIATED TRANSPOSASE SYSTEMS AND METHODS OF USE THEREOF | Massachusetts Institute Of Technology | LEITH, NANCY J | 1636 | §112DP | Non-Final OA | — | Pending | May 12, 2022 |
| 17742127 | NOVEL CRISPR ENZYMES AND SYSTEMS | Massachusetts Institute Of Technology | LEITH, NANCY J | §103§112DP | Non-Final OA | — | Pending | May 11, 2022 | |
| 17761292 | NOVEL TYPE VI CRISPR ENZYMES AND SYSTEMS | Massachusetts Institute Of Technology | MCLEOD, AFRICA MHAIRIE | 1635 | §102§112 | Non-Final OA | — | Pending | Mar 17, 2022 |
| 17689036 | CONCENTRATED NATURAL FOOD ADDITIVE AND METHODS OF PREPARING THE SAME | Wti, Inc. | MORNHINWEG, JEFFREY P | 1793 | §103§112 | Non-Final OA | — | Pending | Mar 08, 2022 |
| 17638355 | CRISPR-ASSOCIATED MU TRANSPOSASE SYSTEMS | Massachusetts Institute Of Technology | SMALL, KATHERINE R | 1633 | §101§102Other | Non-Final OA | — | Pending | Feb 25, 2022 |
| 17681479 | NON-NATURALLY OCCURRING CAPSIDS FOR DELIVERY OF NUCLEIC ACIDS AND/OR PROTEINS | Massachusetts Institute Of Technology | QIAN, CELINE X | 1637 | §103 | Final Rejection | — | Pending | Feb 25, 2022 |
| 17612245 | NON-CLASS I MULTI-COMPONENT NUCLEIC ACID TARGETING SYSTEMS | Massachusetts Institute Of Technology | REGA, KYLE THOMAS | 1636 | §102§103§112 | Non-Final OA | — | Pending | Nov 18, 2021 |
| 17612504 | NOVEL CRISPR-CAS SYSTEMS AND USES THEREOF | Massachusetts Institute Of Technology | MOAZZAMI, NAGHMEH NINA | 1652 | §103§112 | Final Rejection | — | Pending | Nov 18, 2021 |
| 17600799 | METHODS AND COMPOSITIONS FOR CELL THERAPY | The Brigham And Women'S Hospital, Inc. | JOHNSON, ALLISON MARIE | 1638 | §103§112 | Final Rejection | 14d | Pending | Oct 01, 2021 |
| 17311600 | VERY LONG CHAIN FATTY ACID COMPOSITIONS | Epax Norway AS | WHITE, DAWANNA SHAR-DAY | 1627 | §101 | Final Rejection | — | Pending | Jun 07, 2021 |
| 16973061 | CRISPR EFFECTOR SYSTEM BASED AMPLIFICATION METHODS, SYSTEMS, AND DIAGNOSTICS | President and Fellows of Harvard College | RAMIREZ, DELIA M | 1652 | §103§112 | Non-Final OA | — | Pending | Dec 08, 2020 |
| 16936197 | FUNCTIONALIZED SOLID SUPPORT | Massachusetts Institute Of Technology | BUNKER, AMY M | 1684 | §103 | Final Rejection | 9d overdue | Pending | Jul 22, 2020 |
| 16954032 | CAS12A SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED RNA BASE EDITING | Massachusetts Institute Of Technology | HUTSON, RICHARD G | 1652 | §103§112DP | Final Rejection | 20d | Pending | Jun 15, 2020 |
| 16772222 | CAS12B SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED DNA BASE EDITING | Massachusetts Institute Of Technology | PERSONS, JENNA L | 1637 | §112 | Non-Final OA | — | Pending | Jun 12, 2020 |
| 16756134 | SYSTEMS, METHODS, AND COMPOSITIONS FOR TARGETED NUCLEIC ACID EDITING | President and Fellows of Harvard College | STEADMAN, DAVID J | 1656 | DP | Non-Final OA | 3d overdue | Pending | Apr 15, 2020 |
| 16820590 | NON-NATURALLY OCCURRING CAPSIDS FOR DELIVERY OF NUCLEIC ACIDS AND/OR PROTEINS | Massachusetts Institute Of Technology | DACE DENITO, ALEXANDRA GERALDINE | 1636 | §103 | Final Rejection | — | Pending | Mar 16, 2020 |
| 16626396 | NOVEL TYPE VI CRISPR ORTHOLOGS AND SYSTEMS | President and Fellows of Harvard College | HUTSON, RICHARD G | 1652 | Other | Final Rejection | — | Pending | Dec 24, 2019 |
| 16450825 | NOVEL CRISPR ENZYMES AND SYSTEMS | The United States Department of Health and Human Services | RAMIREZ, DELIA M | 1652 | §112 | Non-Final OA | 14d | Pending | Jun 24, 2019 |
| 16450852 | NOVEL CRISPR ENZYMES AND SYSTEMS | The United States Department of Health and Human Services | RAMIREZ, DELIA M | 1652 | §112 | Non-Final OA | 9d | Pending | Jun 24, 2019 |
| 16450699 | NOVEL CRISPR ENZYMES AND SYSTEMS | The United States Department of Health and Human Services | RAMIREZ, DELIA M | 1652 | §112 | Final Rejection | — | Pending | Jun 24, 2019 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial